anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
The invention provides herbal tea, belonging to the field of herbal tea preparation. The herbal tea can effectively avoid the disadvantages that the production cost of the existing herbal tea is high, and the preparation process thereof is complicated, so the existing herbal tea is not suitable for large-scale production. The herbal tea of the invention comprises the following components: 8g of maidenhair, 8g of honeysuckle, 7g of radix ophiopogonis, 7g of cordate houttuynia, 5g of mint leaf, 6g of sweet wormwood, 3g of liquorice and 2g of golden cypress. The method for preparing the herbal tea comprises the following steps: firstly, pulverizing the materials into powder; loading the powder into a pot and adding 3,000g of water to the pot; boiling on the strong heat for 30 minutes; then, switching to the low heat, and boiling until the materials are concentrated into paste; then, drying the concentrated paste in the sun until the paste is dried into dry powder; and then, packaging the obtained dry powder by 10g per bag to obtain the herbal tea readily taken after being infused in hot water. The herbal tea of the invention has the advantages of low production cost and simple production method. The invention is mainly applicable to the production of the herbal tea.
AVELOX has been shown to prolong the QT interval of the electrocardiogram in some patients. Following oral dosing with 400 mg of AVELOX the mean (± SD) change in QTc from the pre-dose value at the time of maximum drug concentration was 6 msec (± 26) (n = 787). Following a course of daily intravenous dosing (400 mg; 1 hour infusion each day) the mean change in QTc from the Day 1 pre-dose value was 10 msec (±22) on Day 1 (n=667) and 7 msec (± 24) on Day 3 (n = 667). 

The drug should be avoided in patients with known prolongation of the QT interval, patients with uncorrected hypokalemia and patients receiving Class IA (for example, quinidine, procainamide) or Class III (for example, amiodarone, sotalol) antiarrhythmic agents, due to the lack of clinical experience with the drug in these patient populations.

Pharmacokinetic studies between AVELOX and other drugs that prolong the QT interval such as cisapride, erythromycin, antipsychotics, and tricyclic antidepressants have not been performed. An additive effect of AVELOX and these drugs cannot be excluded; therefore caution should be exercised when AVELOX is given concurrently with these drugs. In premarketing clinical trials, the rate of cardiovascular adverse events was similar in 798 AVELOX and 702 comparator treated patients who received concomitant therapy with drugs known to prolong the QTc interval.

AVELOX should be used with caution in patients with ongoing proarrhythmic conditions, such as clinically significant bradycardia, acute myocardial ischemia. The magnitude of QT prolongation may increase with increasing concentrations of the drug or increasing rates of infusion of the intravenous formulation. Therefore the recommended dose or infusion rate should not be exceeded. QT prolongation may lead to an increased risk for ventricular arrhythmias including torsade de pointes. No excess in cardiovascular morbidity or mortality attributable to QTc prolongation occurred with AVELOX treatment in over 15,500 patients in controlled clinical studies, including 759 patients who were hypokalemic at the start of treatment, and there was no increase in mortality in over 18,000 AVELOX tablet treated patients in a postmarketing observational study in which ECGs were not performed. Elderly patients using IV AVELOX may be more susceptible to drug-associated QT prolongation [see Use In Specific Populations (8.5)]. In addition, AVELOX should be used with caution in patients with mild, moderate, or severe liver cirrhosis [see Clinical Pharmacology (12.3) and Patient Counseling Information (17.3)].
Membranes formed by the coacervation of a material comprising at least one gelable hydrophilic colloid having amino groups and peptide linkages (e.g. proteins and polyamines) are treated with an aqueous solution of one or more of tannic acid, gallic acid or di-gallic acid to improve their physical characteristics, in particular their impermeability to fluids.  The membranes may be formed by simple or complex coacervation of one or more of the above colloids by any process and they may encapsulate solids, oils, hydrophilic liquid-in-oil and oil-in-hydrophilic liquid emulsions which may contain "active" ingredients which render the preparations suitable as fertilizers, plant growth hormone preparations, bactericides, pesticides, vitamin preparations, medicines and food additives. Treatment is preferably carried out subsequent to the gelling (e.g. by cooling) of the concervate under conditions of time and pH (generally acid) which allow the properties of the product to be varied.  Specified colloids of the above type are gelatine, fibrinogen, polylysine and polyornithine.  Specific examples relate to the treatment of: (a) particles of an aqueous solution of urea-in-corn oil emulsion encapsulated in gelatine with tannic acid, gallic acid and di-gallic acid; (b) a similar preparation comprising 1,2,4,5,6,7,8,8-octachloro-4,17-methano-3a ,4,7, p  7a -tetrahydroindan in place of the urea of (a) with tannic acid; (c) particles of an aqueous solution of chloral hydrate-in-mineral oil emulsion encapsulated in a complex coacervate of gelatine and styrene-maleic anhydride copolymer with tannic acid. Specifications 476,869, 483,550, 573,678, 751,600, 911,483, 929,401, 929,402, 929,403, 929,408, and 929,409 are referred to.
Teratogenic Effects

Pregnancy Category C: There are no adequate and well-controlled trials in pregnant women. In developmental toxicity studies in rats and rabbits, oral administration of sumatriptan to pregnant animals was associated with embryolethality, fetal abnormalities, and pup mortality. When administered by the intravenous route to pregnant rabbits, sumatriptan was embryolethal. Sumatriptan tablets should be used during pregnancy only if the potential benefit justifies the potential risk to the fetus. 

Oral administration of sumatriptan to pregnant rats during the period of organogenesis resulted in an increased incidence of fetal blood vessel (cervicothoracic and umbilical) abnormalities. The highest no-effect dose for embryofetal developmental toxicity in rats was 60 mg/kg/day, or approximately 3 times the maximum recommended human dose (MRHD) of 200 mg/day on a mg/m 2 basis. Oral administration of sumatriptan to pregnant rabbits during the period of organogenesis resulted in increased incidences of embryolethality and fetal cervicothoracic vascular and skeletal abnormalities. Intravenous administration of sumatriptan to pregnant rabbits during the period of organogenesis resulted in an increased incidence of embryolethality. The highest oral and intravenous no-effect doses for developmental toxicity in rabbits were 15 (approximately 2 times the MRHD on a mg/m2 basis) and 0.75 mg/kg/day, respectively. 

Oral administration of sumatriptan to rats prior to and throughout gestation resulted in embryofetal toxicity (decreased body weight, decreased ossification, increased incidence of skeletal abnormalities). The highest no-effect dose was 50 mg/kg/day, or approximately 2 times the MRHD on a mg/m 2 basis. In offspring of pregnant rats treated orally with sumatriptan during organogenesis, there was a decrease in pup survival. The highest no-effect dose for this effect was 60 mg/kg/day, or approximately 3 times the MRHD on a mg/m2 basis. Oral treatment of pregnant rats with sumatriptan during the latter part of gestation and throughout lactation resulted in a decrease in pup survival. The highest no-effect dose for this finding was 100 mg/kg/day, or approximately 5 times the MRHD on a mg/m2 basis.
Allogeneic hematopoietic stem cell transplantation (allo-HSCT) is the major curative therapeutic approach for hematologic neoplasms. After HSCT, patients have a compromised GI mucosal barrier and an altered microbiota, also called dysbiosis. The later could be due to conditioning or use of broad-spectrum antibiotics, and could be accentuate by stress encountered by patients during their therapy management. Recent data have shown that alterations in the intestinal flora are associated with bad outcome, particularly with graft-versus-host disease (GVHD), bacteremia, and reduced overall survival post-transplantation. How intestinal bacteria can modulate the risk of relapse after HSCT is yet unknown. The scientists hypothesize that the variation of some bacterial taxa may influence post-transplant immune reconstitution, particularly invariant Natural Killer T cells.
FIELD: cosmetics. SUBSTANCE: composition for oxidizing coloring of keratin fibers, particularly, hair, contains 2-chlor-6-methyl-3-aminophenol as a color-forming substance in combination with two oxidized bases distinguished from one another. The invention also deals with the method of coloring using proposed composition including an oxidizer and with a set for coloring keratin fibers. Proposed coloring is slightly selective and stable to atmospheric factors and to various treatment (washing, waving). EFFECT: intensive colorings of various shades. 21 cl, 2 tbl, 5 ex
A single blinded randomized clinical trial will be conducted on 26 subjects diagnosed for planter fasciitis from Jawad Club Faisalabad and Alfatah Sports Club, Faisalabad by looking for symptoms and tenderness at heel as mentioned in inclusion criteria and will confirmed by windlass test. Participants who will meet criteria will be requested to give verbal consent and to sign written consent form. After signing consent form participants will be allocated to the group A and Group B by using computerized generated randomization. Group A will receive ultrasound then Active release technique while group B will receive ultrasound and Positional release technique for 4 weeks. Treatment sessions will be 12 sessions, 3 sessions per week on alternative days for 4 weeks. Pain will be measured by Numerical Pain Rating Scale (NPRS), Foot and ankle disability will be assessed by Foot Function Index (FFI), while gait parameters i.e. walking speed will be measured by 4-meter walking test, and step and stride length will be evaluated by measuring tape by taking foot prints before and after the 4 weeks of treatment period. Data will be analyzed through statistical package for the social sciences (SPSS) version 22.
<P>PROBLEM TO BE SOLVED: To provide a hair treatment composition facilitating the inhibition of occurrence of unpleasant hardness in the hair when repairing a damaged hair protein with a protein derivative, and to provide a method of hair treatment.  <P>SOLUTION: The hair treatment composition contains (A) the protein derivative and (B) a diester. The protein derivative (A) is at least one kind selected from among a silylated protein, an acylated protein and a cationized protein. The diester (B) is a diester of cyclohexane-1,4-dicarboxylic acid with polyoxyethylene alkyl ethers. The hair treatment composition preferably contains (C) a hydrolyzed protein besides them. The method of the hair treatment using the hair treatment composition includes subjecting the hair to hairdye treatment by coating a hairdye composition on the hair after applying the hair treatment composition to the hair.  <P>COPYRIGHT: (C)2010,JPO&INPIT
Currently the treatment for patients with end-stage renal disease (stage V) consists of renal replacement therapy (hemodialysis, peritoneal dialysis or renal transplantation), extraordinarily expensive entailing poor quality of life. Our invention is a mixture of carboxylic acids: citric acid, succinic acid, fumaric acid and malic acid, and any possible combinations thereof. This product is preferably used orally or also intravenously, in the treatment of patients with chronic renal failure, hyperammonemia or human conditions having negative nitrogen balance. This product is beneficial in decreasing the serum values of urea and serum ammonium, while promoting by transamination of the oxalacetate formed via succinate, fumarate and malate, the biosynthesis of non-essential amino acids; by transamination of the alpha ketoglutarate formed via citrate, it generates glutamic acid and related amino acids such as glutamine. This treatment prevents, preserves and even improves kidney function. In other patients it delays deterioration of renal function and the urgent need for renal replacement therapy. In others, it is used as a supplemental renal replacement treatment to improve the patient's quality of life and improve laboratory parameters.
The coronavirus disease 2019 (COVID-19) pandemic has not only challenged global health systems but also spurred intense scientific inquiry into its pathophysiology. Among the multifaceted aspects of the disease, coagulation abnormalities have emerged as a significant contributor to morbidity and mortality. From endothelial dysfunction to dysregulated immune responses, various factors contribute to the hypercoagulable state seen in severe COVID-19 cases. The dysregulation of coagulation in COVID-19 extends beyond traditional thromboembolic events, encompassing a spectrum of abnormalities ranging from microvascular thrombosis to disseminated intravascular coagulation (DIC). Endothelial injury induced by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection triggers a cascade of events involving platelet activation, coagulation factor consumption, and fibrinolysis impairment. Moreover, the virus direct effects on immune cells and the cytokine storm further exacerbate the prothrombotic milieu. Unraveling this intricate web of interactions between viral pathogenesis and host responses is essential for elucidating novel therapeutic targets and refining existing management strategies for COVID-19-associated coagulopathy. In the quest to unravel the complex interplay between coagulation and COVID-19, numerous clinical and laboratory studies have yielded invaluable insights into potential biomarkers, prognostic indicators, and therapeutic avenues. Anticoagulation therapy has emerged as a cornerstone in the management of severe COVID-19, although optimal dosing regimens and patient selection criteria remain subjects of ongoing investigation. Additionally, innovative approaches such as targeting specific components of the coagulation cascade or modulating endothelial function hold promise for future therapeutic development.
Progression of acute traumatic brain injury (TBI) into chronic neurodegeneration is a major health problem with no protective treatments. Here, we report that acutely elevated mitochondrial fission after TBI in mice triggers chronic neurodegeneration persisting 17 months later, equivalent to many human decades. We show that increased mitochondrial fission after mouse TBI is related to increased brain levels of mitochondrial fission 1 protein (Fis1) and that brain Fis1 is also elevated in human TBI. Pharmacologically preventing Fis1 from binding its mitochondrial partner, dynamin-related protein 1 (Drp1), for 2 weeks after TBI normalizes the balance of mitochondrial fission/fusion and prevents chronically impaired mitochondrial bioenergetics, oxidative damage, microglial activation and lipid droplet formation, blood-brain barrier deterioration, neurodegeneration, and cognitive impairment. Delaying treatment until 8 months after TBI offers no protection. Thus, time-sensitive inhibition of acutely elevated mitochondrial fission may represent a strategy to protect human TBI patients from chronic neurodegeneration.
Prior to the start of treatment, subjects will have a complete history and physical examination and blood tests to evaluate their overall health. The doctor will also obtain a tissue sample (biopsy) of the tumor taken from the subject's body to evaluate the genes that are expressed within the tumor. Doctors from the University of Michigan will do an analysis on the tissue to understand the genetic nature of each subject's tumor. If the subject's initial surgery or biopsy was done at the University of Michigan, we may already have an adequate sample of their cancer that could be used for this research. In that case, we would be asking for their permission to use this sample for this study. However, if subjects agree to participate in this research study and an adequate sample is not available, they will need to undergo another biopsy procedure for us to obtain a sample of your cancer.

A biopsy of a subject's tumor can be obtained from various sites of their body using a number of different methods. We will select a location that will be the easiest and safest place to biopsy, and that will provide an adequate sample of tumor tissue. Biopsy sites will generally be superficial (for example, lymph nodes, skin nodules, chest wall tumors). The usual method of biopsy will be the placement of a large needle into the tumor to obtain a "core" of tissue. In some situations, we may ask to have a superficial tumor removed in whole or part by a minor surgical procedure. If neither of these methods can be done safely, we may place a thin needle into the tumor and aspirate (suck out) some tumor cells for study. All procedures will be done with local anesthesia (that is, injection of medication directly into the biopsy site to numb the area prior to biopsy) and appropriate care to avoid excessive bleeding or subsequent infection. The doctors will explain the specific biopsy location and technique that fits each subject's situation to them in detail prior to the procedure. They can decide not to go through with the biopsy and withdraw from this research trial at any time.

Subjects will then be given carboplatin and paclitaxel intravenously (through a vein) over 2 hours. This will be repeated every three weeks for a total of six to eighteen weeks. Three weeks is considered a "cycle" and each subject will receive 1 to 6 cycles depending on how their tumor responds and how the treatment is tolerated. Treatment will be stopped if the tumor gets worse or if a subject develops unacceptable side-effects.

Physical examinations, blood tests, and x-rays and/or scans will be done routinely during the therapy so the doctor can check the subject's body and your tumor response to treatment. Blood samples, consisting of 2-3 teaspoonfuls (10-15 cc) each, will be obtained twice every three weeks during the study to evaluate the effect of the treatment on their blood counts, blood electrolytes, liver and kidney function.
* Prior to initiation of IMCIVREE, train patients or their caregivers on proper injection technique. Instruct patients to use a 1-mL syringe with a 28- or 29-gauge needle appropriate for subcutaneous injection.
  * Remove IMCIVREE from the refrigerator approximately 15 minutes prior to administration. Alternatively, warm IMCIVREE prior to administration by rolling the vial gently between the palms of the hands for 60 seconds.
  * Inspect IMCIVREE visually before use. It should appear clear to slightly opalescent, colorless to slightly yellow. Do not use if particulate matter or discoloration is seen.
  * Administer IMCIVREE once daily, at the beginning of the day, without regard to meals.
  * Inject IMCIVREE subcutaneously in the abdomen, thigh, or arm, rotating to a different site each day. Do not administer IMCIVREE intravenously or intramuscularly.
  * If a dose is missed, resume the once daily regimen as prescribed with the next scheduled dose.
Arm 1 participants received the cash only intervention. Households in this arm received 1 mobile cash transfer per month for 6 months.
Proton Chemoradiotherapy followed by surgery. Temozolomide five days per week during radiotherapy for 5 weeks. Proton radiation five days per week for 5 weeks Standard surgery will take place 4-6 weeks after completion of chemoradiation.
A percutaneously administrable base composition which facilitates the percutaneous absorption of drugs and is remarkably reduced in the irritancy against the skin and pharmaceutical composition contain them. The composition comprises 10-60 wt. % of lower alcohol, 10-50 wt. % of humectant, 10-70 wt. % of water, 0.1-15 wt. % of abirritant and 0.1-15 wt. % of absorption promoter. A drug composition is prepared by adding to the above composition various active ingredients such as antitussive, expectorant, skeletal muscle relaxant, antivertiginous drug, narcotic, drug for the circulatory system, and so forth.
High Intensity Functional Training group exercise session. Each session is 45 minutes. Participants will be asked to complete 3 sessions.
Participants are randomized to take two 40 mg lovastatin tablets orally once daily for a total of 12 weeks in a blinded (masked) fashion. For toxicity, the dose could either be adjusted to one 40 mg lovastatin tablet or treatment could be discontinued. In addition to the active ingredient lovastatin, each tablet contained the following ingredients: microcrystalline cellulose, lactose monohydrate, magnesium stearate, and pregelatinized starch. Butylated hydroxyanisole (BHA) was added as a preservative and D\&C Yellow #10, FD\&C Blue #1, and Yellow #6 were added as dyes.
FIELD: medicine.SUBSTANCE: invention relates to medicine, namely to oncology, and can be used to treat gastric cancer patients with limited peritoneal carcinomatosis. The method includes palliative surgery followed by the introduction of cytostatics into the abdominal cavity. After diagnostic laparoscopy and verification of peritoneal carcinomatosis, a phased treatment is carried out. Spend 4 courses of systemic chemotherapy in a combined regimen according to the FLOT scheme every 14 days. 7 days after 4 courses of systemic chemotherapy by laparoscopy, with trocars placed 4-5 cm parumbelically, pneumoperitoneum is reached with a target pressure of 12 mm Hg. and conduct a session of intra-abdominal aerosol chemotherapy at a pressure of 200 psi using antitumor drugs based on anthropometric parameters: cisplatin at a dose of 30 mg/m2diluted in isotonic sodium chloride solution with a volume of 150 ml, doxorubicin 6 mg/m2diluted in isotonic sodium chloride solution with a volume of 50 ml. A week after the operation, an additional 4 courses of systemic chemotherapy are carried out in a combined regimen according to the FLOT scheme every 14 days up to a total of 8 courses. A week later, the second session of intra-abdominal aerosol chemotherapy is repeated: cisplatin at a dose of 30 mg/m2, doxorubicin 6 mg/m2. 14 days later, after the second session of intra-abdominal aerosol chemotherapy, cytoreduction is performed.EFFECT: use of the invention provides stable stabilization and partial resorption of tumor foci in incurable patients due to the long-term maintenance of therapeutic pneumoperitoneum and the direct effect of drugs on tumor cells with the maximum concentration in tumor-affected foci without systemic toxicity.1 cl, 2 dwg, 1 ex